Proprietary alpha-amylase inhibitor formulation from white kidney bean (Phaseolus vulgaris L.) promotes weight and fat loss: a 12-week, double-blind, placebo-controlled, randomized trial.
- 2024-06-03
- Scientific reports 14(1)
- Ralf Jäger
- Sidney Abou Sawan
- Martin Purpura
- Barbara Grube
- Yvette Röske
- Patricia De Costa
- Pee-Win Chong
- PubMed: 38830962
- DOI: 10.1038/s41598-024-63443-8
Study Design
- Type
- Randomized Controlled Trial (RCT)
- Sample size
- n = 81
- Population
- 81 participants with overweight and moderate obesity
- Methods
- Randomized, double-blind, placebo-controlled fashion, 12 weeks of Phase 2 white kidney bean extract (high dose 1000 mg, low dose 700 mg, or placebo) three times a day before meals during a calorie restricted diet
- Blinding
- Double-blind
- Duration
- 12 weeks
- Funding
- Unclear
- Rigorous Journal
White kidney bean (Phaseolus vulgaris L.) extracts can aid weight management by reducing calorie intake from complex carbohydrates through alpha-amylase inhibition. We examined the impact of a proprietary aqueous extract from whole dried white kidney beans standardized by its alpha-amylase inhibitor activity (Phase 2 white kidney bean extract (WKBE)) on weight management in subjects with overweight and moderate obesity. In a randomized, double-blind, placebo-controlled fashion, 81 participants completed the study and ingested either a high dose of Phase 2 (1000 mg, WKBE HIGH), a low dose (700 mg, WKBE LOW), or a matching placebo (microcrystalline cellulose, PLA) three times a day, 30 min before meals, for 12 weeks during a calorie restricted diet. In a dose-dependent manner, Phase 2 significantly reduced body weight, fat mass, BMI, waist, hip and in the WKBE HIGH group thigh circumference. Phase 2 is an effective and safe supplement aiding weight and fat loss. ClinicalTrials.gov identifier NCT02930668.